News

Signing of an Agreement to Establish a Joint Venture for the Manufacture of Biosimilars

Mycenax and RIN Sign License Agreement to Advance ADC Development Using RIN's Proprietary Linker Technology

Mycenax Entered into Non-binding Term Sheet with Japanese Strategic Partners to Advance the Plan of Building Manufacturing Facility and CDMO Business in Japan

Mycenax and SPERA PHARMA Forge Strategic Alliance to Streamline ADC Drug Substance and Drug Product Manufacturing Services

Mycenax Achieves CDMO Transformation Milestones with International Marketing Approvals and Global Expansion

Mycenax Granted Exclusive Rights to RIN Institute’s Proprietary ADC Linker Patents for CDMO Services

Mycenax, Kidswell Bio and Chiome Bioscience Enter into Master Service Agreement for Development of New Biosimilar Drugs

Mycenax Partners to Establish Japan's Domestic Biosimilar Manufacturing Facilities

Mycenax Commences Commercial Manufacturing for Our First Internationally Approved Biopharmaceutical

Mycenax and Sartorius Join Forces to Enhance Biopharmaceutical Manufacturing Solutions